Three-year follow-up of oral BG-12 (dimethyl fumarate) treatment in relapsing remitting multiple sclerosis (RRMS): integrated magnetic resonance imaging (MRI) outcomes from DEFINE, CONFIRM, and ENDORSE

被引：0
|
作者：
Miller, D. H. [1 ]
Fox, R. J. [2 ]
Gold, R. [3 ]
Havrdova, E. [4 ]
Kappos, L. [5 ]
MacManus, D. [1 ]
Yousry, T. [1 ]
Zhang, R.
Yang, M.
Viglietta, V.
Sheikh, S. I.
Dawson, K. T.
Arnold, D. L. [6 ,7 ]
机构：
[1] UCL, Inst Neurol, Queens Sq MS Ctr, London, England
[2] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH 44106 USA
[3] Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany
[4] Charles Univ Prague, Fac Med 1, Prague, Czech Republic
[5] Univ Basel Hosp, Basel Neurol, CH-4031 Basel, Switzerland
[6] NeuroRx Res, Montreal, PQ, Canada
[7] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada
来源：
MULTIPLE SCLEROSIS JOURNAL | 2013年 / 19卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：461 / 462
页数：2
相关论文
共 50 条
  • [31] Clinical efficacy of BG-12 (dimethyl fumarate) for relapsing remitting multiple sclerosis according to prior therapy: an integrated analysis of the phase 3 DEFINE and CONFIRM studies
    Hutchinson, M.
    Gold, R.
    Fox, R. J.
    Havrdova, E.
    Giovannoni, G.
    Zhang, A.
    Hotermans, C.
    Stephan, M.
    Bar-Or, A.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 235 - 235
  • [32] Long-term safety and tolerability of oral BG-12 (dimethyl fumarate) in relapsing-remitting multiple sclerosis: interim results from ENDORSE
    Phillips, J. T.
    Fox, R. J.
    Selmaj, K.
    Raghupathi, K.
    O'Gorman, J.
    Novas, M.
    Sweetser, M. T.
    Viglietta, V.
    Dawson, K. T.
    Gold, R.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 517 - 518
  • [33] An integrated analysis of the clinical and neuroradiological effect of BG-12 (dimethyl fumarate) in subgroups of patients with relapsing-remitting multiple sclerosis from the phase 3 DEFINE and CONFIRM studies
    Bar-Or, A.
    Fox, R. J.
    Gold, R.
    Miller, D. H.
    Arnold, D. L.
    O'Gorman, J.
    Yang, M.
    Sheikh, S. I.
    Viglietta, V.
    Dawson, K. T.
    Hutchinson, M.
    JOURNAL OF NEUROLOGY, 2013, 260 : S13 - S13
  • [34] Effect of BG-12 in subgroups of patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM (Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis) study
    Hutchinson, M.
    Fox, R. J.
    Miller, D.
    Phillips, J. T.
    Kita, M.
    Havrdova, E.
    Yang, M.
    Zhang, R.
    Novas, M.
    Viglietta, V.
    Dawson, K. T.
    JOURNAL OF NEUROLOGY, 2012, 259 : S105 - S106
  • [35] Effects of BG-12 on magnetic resonance imaging outcomes in CONFIRM (Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis), a randomized, placebo-controlled, phase 3 study
    Miller, D.
    Fox, R. J.
    Phillips, J. T.
    Kita, M.
    Hutchinson, M.
    Havrdova, E.
    MacManus, D.
    Yousry, T.
    Zhang, R.
    Viglietta, V.
    Dawson, K. T.
    JOURNAL OF NEUROLOGY, 2012, 259 : S36 - S37
  • [36] Effect of BG-12 in subgroups of patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM (comparator and an oral fumarate in relapsing-remitting multiple sclerosis) study
    Hutchinson, M.
    Fox, R. J.
    Miller, D.
    Phillips, J. T.
    Kita, M.
    Havrdova, E.
    O'Gorman, J.
    Yang, M.
    Novas, M.
    Viglietta, V.
    Dawson, K. T.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 355 - 355
  • [37] Seven-year follow-up of the efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing-remitting multiple sclerosis: integrated analysis of DEFINE, CONFIRM, and ENDORSE
    Gold, R.
    Giovannoni, G.
    Phillips, J. T.
    Fox, R. J.
    Xiao, J.
    Taylor, C.
    Marantz, J. L.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 296 - 297
  • [38] Seven-year follow-up of the efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing-remitting multiple sclerosis: Integrated analysis of DEFINE, CONFIRM, and ENDORSE
    Gold, Ralf
    Giovannoni, Gavin
    Phillips, J. Theodore
    Fox, Robert J.
    Zhang, Annie
    Taylor, Catherine
    Marantz, Jing
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (01) : 156 - 156
  • [39] Effect of BG-12 (Dimethyl Fumarate) in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: Findings from Two Phase 3 Studies (DEFINE and CONFIRM)
    Hutchinson, M.
    Bar-Or, A.
    Fox, R. J.
    Gold, R.
    Giovannoni, G.
    Kita, M.
    O'Gorman, J.
    Yang, M.
    Sheikh, S. I.
    Viglietta, V.
    Dawson, K. T.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (05) : 682 - 683
  • [40] Efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing-remitting multiple sclerosis: eight-year follow-up of an integrated analysis of DEFINE, CONFIRM, and ENDORSE
    Gold, R.
    Giovannoni, G.
    Phillips, J. T.
    Fox, R. J.
    Yang, L.
    Taylor, C.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 313 - 314
12345